Changing Landscape of Diabetic Kidney Disease Treatment, Including the Robert W. Schrier, MD, Endowed Lectureship

Translational Session

https://www.asn-online.org/education/kidneyweek/2023/program-session-details.aspx?sessId=450448

Session Description

The therapeutic landscape of diabetic kidney disease is rapidly evolving. This session opens with a comprehensive overview of the mechanisms of action of novel therapies in the field, as well as unmet needs in the field. Subsequently, updates on recent advances in this arena are provided, with a particular focus on SGLT2 inhibition and GLP1 receptor agonists.

ASN gratefully acknowledges Otsuka America Pharmaceutical, Novartis, Astellas Pharma US, and several individuals for support of the Robert W. Schrier, MD, Endowed Lectureship.

Learning Objective(s)

• Describe the mechanisms of action of novel therapies in diabetic kidney disease
• Summarize the unmet needs in the therapeutic landscape of diabetic kidney disease
• Discuss updates on GLP1 receptor agonists’ use
• Discuss updates on GLP1 receptor agonists’ mechanisms and their use

Learning Pathway(s)

• Diabetic Kidney Disease
• CKD Non-Dialysis

Moderators

• Sylvia E. Rosas, MD, MS, FASN
• Katherine R. Tuttle, MD, FASN